查詢結果分析
來源資料
相關文獻
- Preliminary Results of Helical Tomotherapy for Non-Metastatic Prostate Cancer
- Symptomatic Characteristics and Impact on Quality of Life in Patients with Interstitial Cystitis
- Eosinophilic Cystitis and Ureteritis after Radical Prostatectomy: Case Report and Literature Review
- 膀胱炎
- 談陰道炎與膀胱炎
- 令內外科醫生都困惱的疾病--間質性膀胱炎
- Mesna預防Oxazaphosphorine類藥物所引起的出血性膀胱炎
- Villous Adenomas of the Urinary Tract: Report of Two Cases
- Proctitis Seen in a Colorectal Surgical Clinic
- 放射治療後之出血性膀胱炎
頁籤選單縮合
題名 | Preliminary Results of Helical Tomotherapy for Non-Metastatic Prostate Cancer=導航螺旋刀治療非轉移攝護腺癌之初步結果 |
---|---|
作者 | 郭登宇; 吳樂榮; 謝忱希; 熊佩韋; 謝忱希; | 書刊名 | 放射治療與腫瘤學 |
卷期 | 22:3 2015.09[民104.09] |
頁次 | 頁187-197 |
分類號 | 415.863、415.863 |
關鍵詞 | 影像導引放射治療; 直腸炎; 膀胱炎; 導航螺旋刀; Image-guided radiotherapy; Proctitis; Cystitis; Helical tomotherapy; |
語文 | 英文(English) |
中文摘要 | 目的:發表單一醫學中心使用導航螺旋刀治療非轉移性攝護腺癌之結果。材料與方法:自2006年12月至2013年6月,共85位攝護腺癌病人接受影像導引導航螺旋刀治療。每日使用MVCT影像導引以減少對位誤差。生化控制失敗採用Pheonix定義,副作用的分級根據CTCAE 4.0版本。結果:中位追蹤期為41個月,中位放射劑量至攝護腺為76 Gy。所有病人中有54%為高風險群。四年生化控制率為93.3%,所有中低風險群的病人皆控制良好,高風險的病人有6位生化失敗,其中2位併發骨頭轉移。治療期間,僅分別有4.7%及9.4%的病人出現第二級的腸胃道和泌尿道急性副作用。大於第二級的慢性副作用累積發生率,包含出血性直腸癌、出血性膀胱炎和尿道狹窄則分別為8.2%、4.7%及4.7%。結論:對於攝護腺癌之病人,使用導航螺旋刀之影像導引放射治療,在我們的短期追蹤下有良好的生化控制。治療相關的副作用是可接受的。 |
英文摘要 | Purpose: We report the results of non-metastatic prostate cancer patients treated by helical tomotherapy (HT) in a single institution. Materials and Methods: From December 2006 to June 2013, eighty-five prostate cancer patients receiving image-guided radiation therapy (IGRT) with HT were enrolled in this study. Mega-voltage computed tomography was performed to minimize geographic miss and setup error. The Phoenix definition was used to define biochemical failure. Toxicities were recorded based on Common Terminology Criteria for Adverse Events, version 4.0. Results: The median follow-up interval was 41 months (range, 8-96 months). The median radiation dose delivered was 76 Gy to the whole prostate. Fifty-four percent of patients were in the high-risk category. The 4-year biochemical control rate was 93.3%. All of the patients attributed to the low- and intermediate-risk groups had good biochemical control (n=39). For high-risk group, only 13% (6/46) patients had biochemical failure, and 2 of them also developed bony metastases. During treatment, only 4.7% and 9.4% of the patients experienced grade 2 acute gastrointestinal and genitourinary toxicities, respectively. No grade 3 or 4 acute toxicity was observed. The cumulative incidence of late toxicities of grade 2 or above hemorrhagic proctitis, hemorrhagic cystitis and urethral stricture were 8.2%, 4.7% and 4.7%, respectively. Conclusion: For prostate cancer patients, IGRT with HT results an excellent biochemical control in our limited follow-up period. The treatment-related toxicities were acceptable. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。